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Abstract
Background To evaluate the role of the oral glucose
tolerance test (OGTT) before transplantation and to
examine the risk factors for new-onset diabetes after
transplantation (NODAT) during long-term follow-up
of renal transplant recipients receiving FK-based
therapy.
Methods The study evaluated 378 patients pre-
transplantation using the OGTT and assigned them to
one of three groups: Group 1, normal pattern; Group
2, impaired fasting glucose (IFG)/impaired glucose
tolerance (IGT) pattern (IFG/IGT); and Group 3, DM
pattern.
Results Although the incidence of NODAT was
higherinGroup3thaningroups1and2,nosigniﬁcant
difference was found between the three groups with
regard to graft survival during long-term follow-up.
Multivariateanalysisshowedthatonlyafamilyhistory
of diabetes was a signiﬁcant factor determining
NODAT progression.
Conclusions Impaired glucose tolerance appears to
be a threshold inﬂuencing NODAT; however, it was
not a signiﬁcant factor in graft survival. Careful
monitoring and management based on the result of
the pre-transplantation OGTT appear to prevent the
deterioration of impaired glucose tolerance in renal
transplant recipients receiving FK-based therapy,
even when a pre-operative OGTT shows impaired
glycemic control.
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Introduction
New-onset diabetes after transplantation (NODAT) is
a form of diabetes for which onset or ﬁrst recognition
occurs following organ or cellular transplantation
[1, 2]. For many years, NODAT has been recognized
asacomplicationthatmaycontributetocardiovascular
mortality and graft failure after transplantation [3, 4],
although its importance has been underestimated.
Studieshaveshownthatthecumulativeincidenceof
this condition in transplant recipients is up to 10-fold
higher than that reported in the non-transplanted
population [4–9]. NODAT may develop as a result of
impairment of insulin secretion and/or increased
insulin resistance. Patients with impaired b-cell func-
tion prior to transplantation are at risk of developing
NODAT during treatment with calcineurin inhibitors
[10, 11]. However, insulin resistance has been sug-
gestedasanadditionalmechanismforthedevelopment
of NODAT during maintenance therapy with tacroli-
mus(FK506;FK)ofrenaltransplantrecipients[5].Co-
administrationofsteroidsmaywellbethecauseofthis
increased insulin resistance [10, 12].
The mechanism underlying the development of
NODAT in patients receiving FK treatment remains
unclear [4]. In addition to the effects of the drug, the
underlying disease itself may increase the risk of
developing diabetes mellitus (DM) [13–15].
Various studies have reported tacrolimus (FK506;
FK) therapy to be a risk factor for new-onset diabetes
after transplantation (NODAT). However, no optimal
pre-transplantation monitoring system to predict
NODAT has emerged. In this study, we evaluated
the value of administering the oral glucose tolerance
test (OGTT) before transplantation to predict
NODAT in living-related renal transplant recipients
receiving FK-based therapy. In addition, the possible
effect of FK on the development of IGT was
investigated.
Materials and methods
Patients
We conducted a retrospective analysis of consecutive
adult patients who were transplanted with a living
kidney at our institution in the period from April
2001 to March 2006. We enrolled 800 Japanese
patients who met the following criteria: (1) aged 19
or older; (2) on the waiting list for renal transplan-
tation; (3) with no known history of clinical diabetes;
and (4) with no history of treatment with steroids or
other immunosuppressive agents. All the study pro-
cedures were approved by the Institutional Review
Board of Tokyo Women’s Medical University.
Of the 800 enrolled patients, 378 received
FK-based immunosuppressive therapy, which included
FK, azathioprine (AZ, Azanine
; Tanabe Pharmacy,
Tokyo, Japan), mycophenolate mofetil (MMF, Cell-
Cept
; Roche, Nutley, NJ), and steroids. The remain-
ing 422 who received cyclosporine-based therapy
were excluded from this study because of insufﬁcient
pre-transplant OGTT. Thus, 378 patients whose
follow-up period was[24 months were the subjects
of the present study. The median age of the patients
was 37.5 years (range, 19.7–51.2 years), and the
study population comprised 137 women and 241
men. The primary renal disease was not related to
DM in any of the enrolled patients. The baseline
characteristics of the 378 patients are shown in
Table 1.
Immunosuppressive protocol
All of the patients received FK (Prograf
; Astellas
Fujisawa, Osaka, Japan) immunosuppressive therapy
both before and after transplantation. The immuno-
suppressive regimen has been described previously
[16, 17]. In brief, the induction phase of immuno-
suppression was initiated 7 days before transplanta-
tion, and the target trough level of FK was 8–12 ng/
ml. Post transplantation, the target FK trough levels
in all the patients were 8–12 ng/ml from Day 1 to 30
and 7 to 9 ng/ml from Day 30 to 90; thereafter, the
drug dosage was adjusted gradually to maintain a
trough level of the drug of 4–6 ng/ml. Methylpred-
nisolone (MP, Medorol
; Pﬁzer, Tokyo, Japan)
treatment was also initiated 7 days before transplan-
tation. MP was administered at 250 or 500 mg on
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in the ﬁrst 4 weeks post-transplantation. The MP
dosage was then tapered to 8 mg/day at 3 months
post transplantation. Additional usage of AZ, MMF,
or mizoribine (MZ, Bredinin
; Asahikasei Phar-
macy, Tokyo, Japan) was allowed. Induction with
anti-IL-2 receptor antibody (Basiliximab; 20 mg on
Days 0 and 4) was used in ABO-incompatible renal
transplantation. In addition, to remove anti-A and/or
anti-B antibodies in cases of ABO-incompatible
renal transplantation, the recipients received three or
four sessions of double-ﬁltration plasmapheresis
(DFPP). Splenectomy was also performed on these
patients.
Pre-transplantation OGTT
Accordingtothe2003InternationalConsensusGuide-
lines [18], the patients were divided into three groups
based on their pre-transplantation patterns of glucose
tolerance, as assessed by the OGTT, i.e., normal,
IFG/IGT, and DM. The OGTT, which involved the
administration of 75 g of glucose, was performed
2 weeks before transplantation. The test was per-
formed in the morning on patients who had fasted
overnight,andthefastingbloodglucoselevelsat0,30,
60,and120 minafteroralglucoseloadweremeasured,
beforethestartoforaltreatmentofthepatientswithFK
(given twice daily at 0.10 mg/kg body weight).
Table 1 Patient
characteristics
a Statistical comparison
of groups was performed
using one-way ANOVA
b Data are expressed as the
means ± standard deviation
c There were no
statistically signiﬁcant
differences in the clinical
characteristics of the
patients between the groups,
except for age (P = 0.026)
d Kidney weight-to-
recipient body weight ratio
Groups Group 1
(n = 248,
65.6%)
Group 2
(n = 115,
30.4%)
Group 3
(n = 15,
4.0%)
P value
a
Recipient
Gender 0.075
Men 148 (59.7%) 83 (72%) 10 (66.7%)
Women 100 (40.3%) 32 (27.8%) 5 (33.3%)
Age (year) 36.4 ± 11.3
b 39.6 ± 11.2 40.3 ± 14.1 0.026
c
Body mass index (kg/m
2) 20.5 ± 2.8 21.0 ± 2.9 21.2 ± 2.8 0.325
Duration of hemodialysis (mo) 27 [14–56] 35 [13–83] 29 [15–56] 0.758
Kw/Bw ratio
d 3.24 ± 0.97 3.13 ± 1.03 3.19 ± 0.82 0.641
Cause of end-stage renal disease
Chronic glomerulonephritis 103 (41.5%) 53 (46.1%) 5 (33.3%)
IgA nephropathy 61 (24.6%) 24 (20.9%) 4 (26.7%)
Aplastic kidney 7 (2.8%) 1 (6.7%)
Focal sclerosing glomerulopathy 12 (4.8%) 5 (4.3%)
Membrano proliferative
glomerulonephritis
4 (1.6%) 3 (2.6%)
Cystic kidney 9 (3.6%) 1 (0.9%) 1 (6.7%)
Alport’s syndrome 2 (0.8%) 2 (1.7%)
Purpura nephritis 5 (2.0%) 1 (0.9%)
Rapidly progressive
glomerulonephritis
7 (2.8%) 3 (2.6%)
Nephritis SLE 3 (1.2%)
Donor
Gender 0.169
Men 80 (32.3%) 46(40.0%) 3 (20.0%)
Women 168 (67.7%) 69(60.0%) 12 (80.0%)
Age 55.8 ± 10.0 55.0 ± 10.0 56.0 ± 8.7 0.779
C60 year 93 (37.5%) 39 (33.9%) 6 (40.0%) 0.722
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blood glucose level\100 mg/dl or a 2-h glucose
level\140 mg/dl in the OGTT. The IFG/IGT pattern
was deﬁned as a fasting blood glucose level between
100 and 125 mg/dl or a 2-h glucose level between
140 mg/dl and 199 mg/dl in the OGTT. The DM
pattern was deﬁned as a fasting blood glucose level of
C126 mg/dl or a 2-h serum glucose level of
C200 mg/dl during the OGTT.
Post-transplantation monitoring
The following laboratory tests were performed twice
weekly for 3 months, then weekly for 3 months, and
twice monthly for 1 year: CBC, differential and plate-
let counts, serum creatinine (s-Cr), serum electrolytes,
urinary protein from a spot urine sample, serum
HbA1c, fasting blood sugar, and FK trough level.
Diagnosis and treatment of rejection
All rejections were conﬁrmed by graft biopsy.
Biopsies were performed according to clinical indi-
cations when the serum creatinine level increased by
0.3 mg/dl above baseline, and the patient had symp-
toms such as oliguria or fever. Cellular rejection was
treated with methylprednisolone (MP) 500 mg/day
intravenously for 2 days followed by a tapered
regimen. When rejection was resistant to MP, it
was treated with OKT3 (Orthoclone
, Ortho-Biotech,
Tokyo, Japan) 5 mg/day for 7 days. The criteria for
acute humoral rejection (AHR) were in accordance
with those proposed by Banff criteria [19]. AHR was
treated with OKT3 and three sessions of plasmaphe-
resis. In addition, we performed protocol biopsies in
all patients within 6 months after transplantation.
Subclinical rejection was diagnosed when there was
histological evidence of rejection according to the
1997 Banff criteria [19] in the absence of serum
creatinine elevation. Subclinical rejection, including
borderline changes, was treated with MP 500 mg/day
for 2 days followed by tapering. We did not perform
protocol biopsies between 1990 and 1999.
Diagnosis and treatment of NODAT
For the purposes of this study, NODAT was deﬁned
as a morning fasting blood glucose (FBG) level
of C126 mg/dl or a random blood glucose (RBG) level
of C200 mg/dl on more than one occasion or a 2-h
plasmaglucoselevelof C200 mg/dlintheOGTT [18].
During hospitalization, the morning glucose values
were excluded as a criterion for diagnosing type 2
diabetes in patients with metabolic decompensation
(ketoacidosis,hyperosmolarcoma),patientswithsevere
illnessrequiringadmissiontotheintensivecareunit,and
patients who received intravenous dextrose.
Transient and permanent NODAT were deﬁned as
follows. Patients who had required transient antidia-
betic therapy more than once during the follow-up
period were deﬁned as transient NODAT, and patients
who developed permanent antiglycemic agent-depen-
dent DM were deﬁned as permanent NODAT.
Patients with fasting blood glucose levels
C126 mg/dl were initially placed on dietary restric-
tion; those who were refractory to diet control alone
werestartedonoralhypoglycemicagents, andpatients
who showed an inadequate response to oral hypogly-
cemic agents were started on subcutaneous insulin.
Statistical analysis
Statistical analyses were performed with the SAS
system(version9.1;SASInstitute,Cary,NC).Dataare
presented as means ± standard deviations (SD) and
medians with interquartile ranges or frequencies. One-
way analysis of variance (ANOVA) was used to
compare the three groups for normally distributed
continuous variables, and the Kruskal–Wallis test was
used for other variables. The v
2-test was used to
compare nominally scaled variables. The cumulative
probabilities for graft and patient survival were esti-
mated by the Kaplan–Meier method. To evaluate the
results of the 75-g OGTT in relation to the subsequent
new onset of diabetes, a logistic regression model was
used. A multivariate analysis for the risk factors
inﬂuencing permanent NODAT was performed using
the Cox proportional hazards model with stepwise
selection.A two-tailed Pvalue\0.05 was considered
to indicate a statistically signiﬁcant difference.
Results
Patients’ characteristics
The study was completed for all the patients and
comprised 378 living-related kidney transplantations.
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to the patterns of glucose tolerance assessed in the
pre-transplantation OGTT. Of the total patient pop-
ulation, 248 (65.6%) patients showed the normal
pattern (Group 1), 115 (30.4%) showed the IFG or
IGT pattern (IFG/IGT; Group 2), and 15 (4.0%)
showed the DM pattern (Group 3).
Four percent of patients were identiﬁed at baseline
as having DM by pre-transplant OGTT instead of
having no known history of clinical diabetes and no
history of treatment with steroids or other immuno-
suppressive agents. Such patients cannot strictly be
included in the new-onset diabetes after transplanta-
tion (NODAT) cohort; however, to investigate the
long-term results, we included these patients in this
study for comparison.
There were no statistically signiﬁcant differences
in the clinical characteristics of the patients among
the groups (P[0.05), with the exception of age
(P\0.05).
Sequential changes in serum creatinine, urinary
protein, fasting blood glucose, and blood
hemoglobin A1c after transplantation
Figure 1 shows the sequential changes for each group
in the following: (a) serum creatinine (s-Cr) (mg/dL);
(b) urinary protein (g/day); (c) fasting blood glucose
(mg/dl); and (d) blood hemoglobin A1c (HbA1c; %).
The mean levels of s-Cr and urinary protein were
maintained during the follow-up period for all the
groups. However, the fasting blood glucose levels in
Groups 2 and 3 increased gradually, and that of
Group 3 was[26 mg/dl for the last 3 years. Although
the HbA1c levels were higher ([6.5%) for the last
2 years in Group 3, there were no statistically
signiﬁcant differences between the three groups
(P[0.05). In addition, post-operative FK dose, FK
trough level, and total dosage of steroids did not
differ signiﬁcantly between the three groups after
renal transplantation and throughout the follow-up
period (data not shown).
Patient and graft survival rates
As shown in Fig. 2a, b, the overall 10-year survival
rate of the patients was 98.4%, and there were no
statistically signiﬁcant differences between the three
groups (P[0.05). The Kaplan–Meier 10-year allo-
graft survival estimates for all groups showed that the
5-year graft survival rate was 91.2% in Group 1,
92.5% in Group 2, and 79.4% in Group 3. The 10-
year graft survival rate was 78.8% in Group 1, 74.9%
in Group 2, and 79.4% in Group 3. Although the
5-year graft survival rate was lower in Group 3 than
in Groups 1 and 2, there were no statistically
signiﬁcant differences in the 10-year graft survival
rates between the three groups (P[0.05).
Long-term outcomes for transplanted patients
Pathologic diagnosis of each patient was carried out
using a sample of the protocol or/and episodic biopsy
within 6 months of renal transplantation, based on the
Banff criteria (1997). Chronic rejection was observed
in 83/248 (33.5%) recipients in Group 1. Acute rejec-
tion, including subclinical rejection, was observed in
52/248(21.0%)recipients.The numbers (percentages)
of patients in Groups 2 and 3 who experienced chronic
rejectionwere34(29.6%)and6(40.0%),respectively,
while 21 (18.3%) and 7 (46.7%) patients, respectively,
experienced acute rejection. Although there were no
statistically signiﬁcant differences between the three
groups(P[0.05),boththechronicandacuterejection
rates in Group 3 were higher than those in Groups 1
and 2.
The patient outcomes, including graft failures and
patient deaths, are shown in Table 2. There were no
statistically signiﬁcant differences in relation to any
of these items between the groups (P[0.05).
However, a signiﬁcantly higher incidence of any
graft failure type was observed in Group 3, when
compared with Group 1 (P\0.05).
Incidence of NODAT based on pre-transplantation
OGTT patterns
Seventeen (6.9%) of the 248 patients in Group 1
developed hyperglycemia that necessitated transient
antidiabetic therapy (transient NODAT), and six
(2.4%) patients developed permanent antiglycemic
agent-dependent NODAT (permanent NODAT).
Eleven (9.6%) of the 115 patients in Group 2
developed transient NODAT, and seven (6.1%)
Int Urol Nephrol (2010) 42:935–945 939
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15 patients in Group 3 developed transient NODAT,
and three (20.0%) developed permanent NODAT
(Table 3). Interestingly, the remaining seven (46.7%)
patients in Group 3 did not develop transient or
permanent NODAT.
There were no statistically signiﬁcant differences
between Group 1 and Group 2 with regard to the
incidences of transient and permanent NODAT
(P[0.05), although the odds ratios, especially those
for permanent NODAT, tended to be higher in Group
2( P[0.05). The incidences of transient and perma-
nent NODAT in Group 3 were signiﬁcantly higher
than those in Groups 1 and 2.
Comparison of patients with non-diabetic,
transient antidiabetic therapy–requiring
and permanent antidiabetic therapy–requiring
conditions
The characteristics of the recipients who developed
NODAT are summarized in Table 4. The family
history of DM was ascertained by strict inquiry
before transplantation. The time for diagnosis of
NODAT ranged from 14 to 326 days, with a mean of
40.9 ± 6.38 days post transplantation. During the
follow-up period, blood glucose control improved
and became normalized in 33 patients who were
managed with dietary restriction alone, transient oral
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Fig. 1 Long-term sequential changes in serum creatinine (a),
urinary protein (b), fasting blood glucose (c), and blood
hemoglobin A1c after transplantation. The mean levels of s-Cr
and urinary protein were maintained during the follow-up
period in all groups. However, the fasting blood glucose levels
in Groups 2 and 3 increased gradually and that of Group 3 was
[126 mg/dl for the last 3 years. Although HbA1c levels were
higher ([6.5%) for the last 2 years in Group 3, there were no
statistically signiﬁcant differences between the three groups
(P[0.05). Group 1, thin line; Group 2, dotted line; Group 3,
thick line; *, statistically signiﬁcant difference between groups
(P\0.05)
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123hypoglycemic agents or transient insulin administra-
tion, and who had a previous diagnosis of transient
NODAT. At the end of the ﬁrst year, diabetes
persisted in 16 patients, four of whom were treated
with a combination of insulin and oral antidiabetic
medication and 12 of whom were treated with insulin
alone; all 16 patients were considered to have
permanent NODAT. Compared with the non-diabetic
patients, there were no statistically signiﬁcant differ-
ences in the clinical characteristics of the patients
between the groups (P[0.05), with the exception of
family history of diabetes (P\0.01). Family history
was also signiﬁcant in the multivariate analysis and
adversely inﬂuenced NODAT. Although no statistical
signiﬁcance was found in this study, these transient
and permanent NODAT recipients tended to have
higher body mass index (BMI) values than did the
non-diabetic recipients (P[0.05).
Discussion
NODAT remains a serious complication of therapy
with immunosuppressive drugs, in that it not only
increases the risks of graft loss and mortality, but also
predisposes the patients to all the complications of
diabetes, including retinopathy and neuropathy. The
diabetogenic effects of immunosuppressive therapies
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Fig. 2 a Kaplan–Meier
estimates of patient
survival. All groups
demonstrated an excellent
patient survival rate
throughout the follow-up
period. No statistically
signiﬁcant difference was
detected between groups
(P[0.05). b Kaplan–
Meier estimates of graft
survival. Patients who
exhibited the DM pattern
(Group 3) showed a poorer
allograft survival rate
2 years after transplantation
(P\0.05; Group 3 versus
Group 1 and 2); however,
no statistically signiﬁcant
difference was detected
between groups at
5–12 years after
transplantation (P[0.05)
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123after organ transplantation are well-recognized [20].
However, since the deﬁnition of NODAT remains
unclear, the reported incidences of NODAT have
varied.
The criteria that we used in the present study for
diagnosing DM in the post-transplantation period are
the same as the 2003 International Consensus Guide-
lines [18] for the deﬁnition of DM in clinical practice.
Until quite recently, the criteria used to diagnose
NODAT varied among studies [20, 21]. Most deﬁni-
tions of NODAT in the literature are based on random
glucose testing or fasting glucose levels[140 mg/dl.
Hjelmesaeth et al. [22] and Mathew et al. [21]
reported NODAT and IGT rates of 18 and 31%, and
21.4and24.1%,respectively.Inthesepreviousstudies,
only patients with overt diabetes were included, and
those with IFG/IGT were excluded. Unfortunately, we
could not perform post-transplantation OGTT in the
present study; thus, the incidence of NODAT reported
here is likely underestimated.
Immunosuppressive agents that have adverse
effects on glucose tolerance include corticosteroids,
cyclosporine, and in particular, FK. Several reports
have shown an increased incidence of NODAT
among transplant recipients receiving FK. Todo
et al. [23] ﬁrst described the association between
NODAT and FK in a cohort of 121 liver transplant
recipients, 10 of whom developed insulin-requiring
NODAT after transplantation. Weir et al. [5]
described a signiﬁcantly higher incidence of NODAT
among renal transplant recipients treated with FK
(8.3–25.4%), when compared to those treated with
cyclosporine (2.2–7.0%).
In addition, several risk factors predispose patients
to developing NODAT, including increased age, a
family history of diabetes, increased BMI (obesity),
Table 2 Rates of rejection
and patient outcomes
a Statistical analysis
between groups was
performed using one-way
ANOVA
Group 1
(n = 248)
Group 2
(n = 115)
Group 3
(n = 15)
P value
a
Rejection episode
Chronic rejection 83 (33.5%) 34 (29.6%) 6 (40.0%) 0.590
Acute rejection 52 (21.0%) 21 (18.3%) 7 (46.7%) 0.064
Long-term outcome
Graft failure 24 (9.7%) 15 (12.8%) 4 (26.7%) 0.065
Death with function 4 (1.6%) 2 (1.7%)
Acute rejection 4 (1.6%) 1 (6.7%)
Chronic rejection 11 (4.4%) 8 (6.8%) 1 (6.7%)
Non-compliance 1 (0.3%) 1 (0.9%)
Drug nephrotoxicity 1 (0.3%) 1 (0.9%)
Post-transplantation nephritis 2 (0.8%) 3 (2.6%) 1 (6.7%)
Others 1 (0.4%) 1 (6.7%)
Death 4 (1.6%) 2 (1.7%) 0.880
Table 3 Incidence of NODAT
NODAT patients
Group No. of patients Transient NODAT patients Permanent NODAT patients
Incidence Odds ratio (95% CI) P value Incidence Odds ratio (95% CI) P value
Group 1 248 17 (6.9%) 1.00 6 (2.4%) 1.00
Group 2 115 11 (9.6%) 1.71 (0.80–3.66) 1.160 7 (6.1%) 2.59 (0.85–7.88) 0.084
Group 3 15 5 (33.3%) 6.85 (2.10–22.33) \0.001
a 3 (20.0%) 10.17 (2.26–45.66) \0.001
b
CI conﬁdence interval
a,b Group 3 vs. Group 1: Chi-square
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African or Hispanic descent [24, 25]. In the present
study, only family history of diabetes was identiﬁed
as a risk factor for NODAT development, which is
dissimilar to previous reports.
As described earlier, we screened patients for
diabetes risk factors, and all the recipients were
evaluated by OGTT pre-transplantation. In addition,
throughout the follow-up period, the patients under-
went laboratory testing for fasting plasma glucose,
urinary protein, and HbA1c. The laboratory tests
were monitored regularly in all the post-transplanta-
tion recipients twice weekly for 3 months, then
weekly for 3 months, twice monthly for 1 year, and
once per month over the next 10 years.
The management of NODAT was similar to that of
diabetes in the non-transplant population and included
dietary and lifestyle modiﬁcations. Patients who
showed impaired glycemic control were promptly
subjected to dietary restrictions; only those who were
refractory to the dietary control intervention method
were initiated on oral hypoglycemic agents. In
selecting the oral agents and/or insulin, the medical
proﬁle of each individual was considered carefully.
Corticosteroid exposure was limited as much as
possible, and reducing the calcineurin inhibitor dos-
age was considered to be prudent.
Interestingly,sevenofthe15patientsinGroup3did
not develop transient or permanent NODAT; instead,
theyshowedaDMpatterninthepre-transplantOGTT.
Although this mechanism could not be elucidated in
this study, this result suggests that careful monitoring
andmanagement aftertransplantation canpreserve the
non-diabetic state of some recipients even if pre-
operativeOGTT showsthe IFG/IGTor DM pattern. In
this study, the occurrence of NODAT had no effect on
long-term patient and graft outcome. This result also
contradicts the literature. Although there were signif-
icant differences in the numbers of transient and
permanent NODAT patients in Group 3 (Table 3),
such monitoring and management yielded excellent
long-term graft survival and patient safety.
Table 4 Characteristics of non-diabetic patients and diabetic patients with transient or permanent NODAT, and multivariate analysis
of risk factors for the development of permanent NODAT
Characteristics Non-diabetic
patients (n = 329)
Transient NODAT
patients (n = 33)
P value
b Permanent NODAT
patients (n = 16)
P value
b
Age at transplantation (year) 36.4 ± 12.4
a 39.6 ± 10.4 0.16 40.3 ± 13.5 0.23
Male gender 211 (64.1%) 20 (60.6%) 0.69 10 (62.5%) 0.89
Family history of diabetes (%) 13 (6.5%) 10 (30.3%) \0.01
c 8 (50%) \0.01
d
BMI (kg/m
2) at transplantation 20.1 ± 2.6 21.0 ± 2.7 0.07 21.4 ± 2.6 0.056
BMI at 12 months 21.8 ± 5.5 23.2 ± 3.2 0.16 24.1 ± 3.8 0.10
Dialysis duration (months) 38.2 ± 43.5 36.4 ± 36.2 0.82 42.4 ± 52.6 0.71
Donor
Male gender (%) 109 (33.1%) 13 (39.4%) 0.47 7 (43.8%) 0.79
Age 54.8 ± 11.0 55.4 ± 10.5 0.77 56.6 ± 7.8 0.52
C60 year 96 (29.2%) 16 (48.5%) 0.022 7 (43.8%) 0.15
One acute rejection episode (%) 76 (23.1%) 11 (33.3%) 0.72 10 (62.5%) 0.24
Serum creatinine at 1 year (mg/dl) 1.42 ± 0.51 1.50 ± 0.62 0.42 1.51 ± 0.56 0.50
Arterial hypertension (%) 85 (25.8%) 12 (36.4%) 0.49 10 (62.5%) 0.12
Risk factors for the development of permanent NODAT (multivariate analysis) v
2 P value Hazard ratio 95% CI
Family history of diabetes 9.09 0.013 8.40 3.12–26.5
CI conﬁdence interval
a Data are expressed as means ± standard deviation or frequencies
b Compared with the non-diabetic patients
c,d Family history of diabetes was signiﬁcantly higher in both transient and permanent NODAT patients than in non-diabetic patients
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123In the present study, we followed up on patients
who showed different glucose tolerance patterns in
pre-transplantation OGTT, and we evaluated whether
pre-operative OGTT is useful in predicting the
occurrence of NODAT in FK-treated renal transplant
recipients. It is widely known that end-stage renal
disease and dialysis are associated with impaired
glycemic control, which is caused by increased
insulin resistance and impaired insulin secretion
[21, 26]. Notably, before FK administration, 130
patients (34.4%) showed impaired glycemic control,
as revealed by the pre-transplantation OGTT. Thus,
careful pre-transplantation screening and evaluation
are required for predicting the occurrence of
NODAT, and post-transplantation monitoring and
management in consideration of results of pre-
transplantation OGTT may prevent progression to
NODAT.
In conclusion, we determined that pre-operative
OGTT is useful for predicting the occurrence of
NODAT in renal transplant recipients who are
receiving FK and who show the DM or IFG/IGT
pattern in pre-operative OGTT. Even when pre-
operative OGTT shows impaired glycemic control,
careful monitoring and management after transplan-
tation may maintain the non-diabetic state.
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